FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * F2 Bioscience IV L.P.   2. Issuer Name and Ticker or Trading Symbol Radius Health, Inc. [RDUS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) UGLAND HOUSE, SOUTH CHURCH STREET, PO BOX 309 3. Date of Earliest Transaction (Month/Day/Year) 07/10/2014 (Street) GEORGE TOWN, E9 KY1-1104 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/10/2014   J   251,680 (1) D (1) 335,820 I By Fund (2) Common Stock 07/15/2014   J   335,820 (1) D (1) 0 I By Fund (2) Common Stock               1,794,983 D (3)   Common Stock               871,851 I By Fund (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
F2 Bioscience IV L.P. UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 GEORGE TOWN, E9 KY1-1104		X
F2 Bioscience IV GP Ltd. UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 GEORGE TOWN, E9 KY1-1104		X
F2 Capital Ltd PO BOX 3175 ROAD TOWN TORTOLA, D8 VG 1110		X
Priestley Katherine UGLAND HOUSE, SOUTH CHURCH STREET PO BOX 309 GEORGE TOWN, E9 KY1-1104		X
F2 Bio Ventures V L.P. KINGSTON CHAMBERS P.O. BOX 173 ROAD TOWN, TORTOLA, D8 VG 1110		X
F2 Bio Ventures GP Ltd. KINGSTON CHAMBERS P.O. BOX 173 ROAD TOWN, TORTOLA, D8 VG 1110		X
Globeways Holdings Ltd 3RD FLOOR, GENEVE PLACE WATERFRONT DRIVE, PO BOX 3175 ROAD TOWN, TORTOLA, D8 00000		X

Signatures

/s/ Morag Law, attorney-in-fact for F2 Bioscience IV, L.P.		01/13/2015
**Signature of Reporting Person		Date
/s/ Morag Law, attorney-in-fact for F2 Bioscience IV GP Ltd.		01/13/2015
**Signature of Reporting Person		Date
/s/ Morag Law, attorney-in-fact for F2 Capital Limited		01/13/2015
**Signature of Reporting Person		Date
/s/ Morag Law, attorney-in-fact for Katherine Priestley		01/13/2015
**Signature of Reporting Person		Date
/s/ Morag Law, attorney-in-fact for F2 Bio Ventures V, L.P.		01/13/2015
**Signature of Reporting Person		Date
/s/ Morag Law, attorney-in-fact for F2 Bio Ventures GP Ltd.		01/13/2015
**Signature of Reporting Person		Date
/s/ Morag Law, attorney-in-fact for Globeways Holdings Ltd.		01/13/2015
**Signature of Reporting Person		Date
/s/ Morag Law, attorney-in-fact for F2 Bioscience VI, L.P.		01/13/2015
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Reflects a distribution by F2 Bioscience VI L.P. ("F2 Science") to a limited partner.
(2)	The reported securities are owned directly by F2 Science. F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 Science. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 Science. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
(3)	The reported securities are owned directly by F2 Bioscience IV L.P. ("F2 IV"). F2 IV GP is the General Partner of F2 IV. Katherine Priestley and Globeways are members of F2 IV GP. F2 Capital is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
(4)	The reported securities are owned directly by F2 Bio Ventures V L.P. ("F2 Bio"). F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.